MX9200882A - Preparacion de factor ix. - Google Patents

Preparacion de factor ix.

Info

Publication number
MX9200882A
MX9200882A MX9200882A MX9200882A MX9200882A MX 9200882 A MX9200882 A MX 9200882A MX 9200882 A MX9200882 A MX 9200882A MX 9200882 A MX9200882 A MX 9200882A MX 9200882 A MX9200882 A MX 9200882A
Authority
MX
Mexico
Prior art keywords
factor
contained
preparations
disclosed
derived
Prior art date
Application number
MX9200882A
Other languages
English (en)
Inventor
Chin C Huang
Takashi Enkoji
Laura Ho
Richard R Kleszynski
Richard L Weeks
Fred Feldman
Original Assignee
Rhone Poulenc Rorer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Int filed Critical Rhone Poulenc Rorer Int
Publication of MX9200882A publication Critical patent/MX9200882A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
MX9200882A 1991-03-01 1992-02-28 Preparacion de factor ix. MX9200882A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66292791A 1991-03-01 1991-03-01

Publications (1)

Publication Number Publication Date
MX9200882A true MX9200882A (es) 1992-09-01

Family

ID=24659784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9200882A MX9200882A (es) 1991-03-01 1992-02-28 Preparacion de factor ix.

Country Status (17)

Country Link
US (3) US6063909A (es)
EP (1) EP0573605B1 (es)
JP (1) JP3418621B2 (es)
AT (1) ATE195877T1 (es)
AU (1) AU671586B2 (es)
BR (1) BR9205700A (es)
CA (1) CA2105282C (es)
DE (1) DE69231401T2 (es)
DK (1) DK0573605T3 (es)
ES (1) ES2150914T3 (es)
FI (1) FI114969B (es)
GR (1) GR3034946T3 (es)
MX (1) MX9200882A (es)
NO (1) NO315856B1 (es)
RU (1) RU2142806C1 (es)
SG (1) SG48282A1 (es)
WO (1) WO1992015324A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0573605B1 (en) * 1991-03-01 2000-08-30 Rhone-Poulenc Rorer International (Holdings) Inc. Preparation of factor ix
CA2143125C (en) * 1992-08-27 2008-09-23 Koenraad Mertens Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DE19506633A1 (de) * 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
PT937158E (pt) * 1996-10-31 2001-06-29 Roche Diagnostics Gmbh Processo para a determinacao da actividade catalitica de factor ixa
AU2002226028A1 (en) * 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
EP1617799A2 (en) * 2003-04-09 2006-01-25 Wyeth Hemophilia treatment by inhalation of coagulation factors
US8012498B2 (en) 2004-07-12 2011-09-06 Sandhya Goyal Topical gel formulation comprising organophosphate insecticide and preparation thereof
US8158139B2 (en) * 2004-07-12 2012-04-17 Taro Pharmaceuticals North America, Inc. Topical gel formulation comprising organophosphate insecticide and preparation thereof
US7560445B2 (en) * 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
KR20120118028A (ko) 2010-01-18 2012-10-25 노보 노르디스크 헬스 케어 악티엔게젤샤프트 혈액 응고 인자의 정제
ES2610529T3 (es) * 2010-03-30 2017-04-28 Octapharma Ag Un procedimiento de purificación de proteínas dependientes de vitamina K, tales como el factor de coagulación IX
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) * 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
DE3101752A1 (de) * 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
US4379085A (en) * 1982-05-14 1983-04-05 American National Red Cross Heat stabilization of plasma proteins
US5614500A (en) 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
US5055557A (en) * 1983-03-04 1991-10-08 Scripps Clinic & Research Foundation Ultrapurification of factor IX and other vitamin K-dependent proteins
DE3485711D1 (de) * 1983-03-04 1992-06-17 Scripps Clinic Res Immunoadsorbens und verfahren zur zurueckgewinnung von vitamin-k-abhaengigen proteinen mittels dieses adsorbens.
DE3473407D1 (en) * 1983-05-02 1988-09-22 Immuno Ag Method of inactivating pathogens
JPS60132912A (ja) * 1983-12-21 1985-07-16 Kao Corp シヤンプ−組成物
US4770999A (en) * 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
FR2600334B1 (fr) 1986-06-23 1989-05-12 Transgene Sa Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
DE3877529T2 (de) 1987-10-23 1996-11-07 Centre Regional De Transfusion Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
JPH01258700A (ja) 1988-04-05 1989-10-16 Green Cross Corp:The 血液凝固第4因子の精製方法
DE3826792C1 (es) * 1988-08-06 1989-07-06 Biotest Pharma Gmbh, 6072 Dreieich, De
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DE3914869C1 (es) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De
AT402261B (de) * 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
EP0573605B1 (en) * 1991-03-01 2000-08-30 Rhone-Poulenc Rorer International (Holdings) Inc. Preparation of factor ix

Also Published As

Publication number Publication date
GR3034946T3 (en) 2001-02-28
EP0573605A1 (en) 1993-12-15
WO1992015324A1 (en) 1992-09-17
NO315856B1 (no) 2003-11-03
JP3418621B2 (ja) 2003-06-23
US6280729B1 (en) 2001-08-28
DE69231401T2 (de) 2001-02-08
FI933814A0 (fi) 1993-09-01
FI933814A (fi) 1993-09-01
FI114969B (fi) 2005-02-15
CA2105282C (en) 2002-09-24
EP0573605B1 (en) 2000-08-30
US6043215A (en) 2000-03-28
JPH06505494A (ja) 1994-06-23
AU1642992A (en) 1992-10-06
SG48282A1 (en) 1998-04-17
DE69231401D1 (de) 2000-10-05
DK0573605T3 (da) 2001-01-02
EP0573605A4 (en) 1994-11-23
NO933114L (no) 1993-09-01
BR9205700A (pt) 1994-06-28
NO933114D0 (no) 1993-09-01
ATE195877T1 (de) 2000-09-15
RU2142806C1 (ru) 1999-12-20
AU671586B2 (en) 1996-09-05
ES2150914T3 (es) 2000-12-16
CA2105282A1 (en) 1992-09-02
US6063909A (en) 2000-05-16

Similar Documents

Publication Publication Date Title
MX9200882A (es) Preparacion de factor ix.
DE3680271D1 (de) Thrombolytische zusammensetzung und verfahren zu deren herstellung.
ATE148165T1 (de) Stabilisierung von hochgereinigten proteinen
RU93053992A (ru) Способ очистки и хранения фактора ix, водный раствор очищенного фактора ix, композиция, содержащая фактор ix, способ лечения
SE8701921L (sv) Ny farmaceutisk anvendning
NO2006006I1 (no) Aktivert protein C
ATE117313T1 (de) Stabile lösungen von rebeccamycinderivaten sowie deren herstellung.
SE8704832L (en) Prepn. for dissolving caries - comprises nitrogen-contg. cpds. and sodium hypochlorite
DE68908958D1 (de) Peptide.
DE3855751D1 (en) Hypoglycemische peptide
SE9502927D0 (sv) Solution containing IGF-I
GR77250B (es)
DE68905796D1 (de) Chromoglycinsaeure-natriumsalz enthaltende aerosolzubereitungen.
ATE193537T1 (de) Phosphorylierte derivate von verbindungen mit antiinflammatorischen oder analgetischer wirkung
ES2067140T3 (es) Compuestos fenilester de acido benzoico y composiciones inhibidoras de la elastasa que contienen los mismos.